AtriCure 과거 순이익 실적
과거 기준 점검 3/6
AtriCure의 수입은 연평균 -18.6%의 비율로 감소해 온 반면, Medical Equipment 산업은 수입이 연평균 18.2% 증가했습니다. 매출은 연평균 16.3%의 비율로 증가해 왔습니다. AtriCure의 자기자본이익률은 2%이고 순이익률은 1.9%입니다.
핵심 정보
-18.62%
순이익 성장률
-18.36%
주당순이익(EPS) 성장률
| Medical Equipment 산업 성장률 | 8.90% |
| 매출 성장률 | 16.31% |
| 자기자본이익률 | 2.04% |
| 순이익률 | 1.85% |
| 최근 순이익 업데이트 | 30 Jun 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • Sep 03
ATRC: New STS Quality Metric Will Support Future Repricing Potential
Analysts have lifted their AtriCure fair value estimate to $64 from $55, pointing to updated price targets that reflect expectations around the new STS Quality Metric and its potential to support additional EnCompass Clamp and open ablation revenue, while also weighing the impact of fresh competition in left atrial appendage exclusion and mixed target moves from BTIG and UBS. Analyst Commentary Bullish analysts see the new STS Quality Metric as an important support for AtriCure, particularly for adoption of the EnCompass Clamp in surgery patients who already have atrial fibrillation.Seeking Alpha • Aug 21
AtriCure: Promising Cardiovascular Surgical Platform
Summary AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we’ve already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering. Nevertheless, ATRC’s valuation today doesn’t seem excessive, and if management delivers on its targets, the stock could be rewarding for long-term investors. Read the full article on Seeking Alpha
내러티브 업데이트 • Jul 01
ATRC: Competitive Rollout And Index Inclusion Are Expected To Support Upside
Analysts have adjusted their AtriCure fair value estimate to $47.00 from $52.78, reflecting updated assumptions on growth, profitability, and future P/E in light of recent research that highlights both emerging AtriClip competition and confidence in the company's ability to defend its share and execute a targeted rollout strategy. Analyst Commentary Recent Street research on AtriCure focuses on how the company might respond to new competition for AtriClip while still supporting its current valuation framework.분석 기사 • Jun 21
AtriCure (ATRC) Stock Could Be 45.4% Undervalued As Growth Narrative Faces A Cash Flow Test
AtriCure (ATRC) is back on investor watchlists after recent trading left the stock around $28.80, inviting fresh scrutiny of its valuation against a backdrop of mixed short term and longer term returns. See our latest analysis for AtriCure. The recent 1 day share price return of 6.2% contrasts with weaker longer term performance, with the year to date share price return down 26.7% and the 5 year total shareholder return down 64.1%, suggesting recent momentum is rebuilding from a lower...내러티브 업데이트 • Jun 17
ATRC: Accelerated BoxX-NoAF Trial And Firmer P E Frame Will Support Repricing
Analysts have nudged their average AtriCure price target higher by $2, citing recent research that points to slightly stronger revenue and margin expectations, which in turn support a modestly lower discount rate and P/E assumption. Analyst Commentary Recent research on AtriCure points to a more constructive tone, with bullish analysts highlighting factors they see as supportive of the latest price target adjustments and valuation assumptions.내러티브 업데이트 • Jun 03
ATRC: Raised Coverage And P E Outlook Will Support Bullish Repricing
Analysts have raised their AtriCure price target by $2, citing recent supportive research that points to a more constructive view on the stock and its long term assumptions around growth, margins, and future P/E levels. Analyst Commentary Recent research points to a more constructive stance on AtriCure, with bullish analysts emphasizing how current expectations for growth, margins, and future P/E levels could support the stock’s long term investment case.내러티브 업데이트 • May 19
ATRC: Product Moat And Clinical Data Will Support Bullish Repricing
Analysts have trimmed their fair value estimate for AtriCure to $55 from $64, reflecting updated assumptions for slightly softer revenue growth, a modestly lower profit margin outlook, and a reduced future P/E multiple, even as recent research points to ongoing product progress and a still supportive view from several firms despite rising competitive concerns. Analyst Commentary Recent research on AtriCure highlights a split in views, with some firms flagging competitive threats and others pointing to ongoing execution in sales, earnings, and product development as support for current valuations.
내러티브 업데이트 • May 01
ATRC: Clinical Strength And 2026 Profitability Are Expected To Offset New Competition
The updated analyst price target for AtriCure now reflects a modest valuation reset in the mid to high $50 range, as analysts weigh recent target cuts and rating downgrades against ongoing confidence in the company's product pipeline, clinical data strength, and prospects for durable revenue growth with improving profitability. Analyst Commentary Recent research has introduced a mix of optimism and caution around AtriCure, with bullish views on the product portfolio and clinical positioning sitting alongside fresh concerns about competition and long term growth durability.내러티브 업데이트 • Apr 17
ATRC: Clinical Moat And 2026 Profitability Are Expected To Withstand New Entrant
Narrative Update on AtriCure The updated analyst price target for AtriCure has edged down by about $0.23, reflecting a slightly higher discount rate and lower expected future P/E. Analysts are weighing new competitive risks against continued confidence in the company’s product pipeline, clinical data, and profitability progress.내러티브 업데이트 • Apr 02
ATRC: 2026 Guidance And Clinical Moat Are Expected To Outlast New Competition
Analysts have modestly reduced the AtriCure price target by $1.31 to $36.41. This reflects both lower published Street targets in response to emerging competition and continued confidence in revenue growth, margins, and the company’s clinical and product positioning.내러티브 업데이트 • Mar 19
ATRC: 2026 Guidance And Clinical Moat Will Confront Emerging Competition
Analysts have trimmed AtriCure's average price target by a few dollars to around the mid $50s. This reflects a mix of confidence in recent sales and EPS outperformance and product progress, tempered by concerns about emerging competition in left atrial appendage closure products and long term growth risks.내러티브 업데이트 • Mar 04
ATRC: 2026 Guidance And New Dual Energy Platform Will Shape Upside
Analysts have adjusted their outlook on AtriCure, with our updated fair value estimate moving from $36.00 to about $37.72. This change reflects a mix of lower Street price targets, concerns about emerging competition, and continued confidence in the company’s product progress, clinical data, and profitability trajectory.내러티브 업데이트 • Feb 18
ATRC: JPMorgan Downgrade And 2026 Profit Outlook Will Shape Risk Balance
Analysts have revised their AtriCure price target from $40.00 to $36.00, citing updated assumptions around discount rates, revenue growth, profit margins, and elevated future P/E expectations in light of recent research, including the JPMorgan downgrade. Analyst Commentary Recent commentary points to a more cautious stance on AtriCure, with the revised US$36.00 target reflecting what bearish analysts see as a need to factor in higher risk around execution, profitability, and future growth expectations.내러티브 업데이트 • Feb 04
ATRC: Dual Energy Platform Trial Progress Will Support Long Term Upside Potential
Analysts have adjusted their price targets on AtriCure, reflecting updated assumptions around discount rates, revenue growth, profit margins and a revised future P/E of 134.36x. Collectively, these factors support a fair value estimate of about $52.78 per share.내러티브 업데이트 • Jan 21
ATRC: Future Trial Progress Will Drive Confidence In Long Term Outlook
AtriCure's updated analyst price target has increased from US$50.00 to about US$52.78. Analysts cite adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers of this change.내러티브 업데이트 • Jan 06
ATRC: Dual Energy Ablation Breakthrough Will Drive Bullish Repricing
Analysts have maintained their price target on AtriCure at US$64.00, citing updated assumptions for slightly higher revenue growth, wider profit margins, a modestly higher discount rate, and a lower future P/E multiple as key inputs to their valuation work. What's in the News AtriCure announced successful first in human procedures using its dual energy platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation, performed at Victorian Heart Hospital in Australia under Monash Health HREC approval (Key Developments).내러티브 업데이트 • Dec 15
ATRC: Dual Energy Platform And Noaf Trial Will Drive Bullish Repricing
Analysts have raised their price target on AtriCure by approximately 7 percent to 64 dollars per share, reflecting greater confidence in the company’s improving profit margin outlook and more favorable long term valuation assumptions, despite a slightly higher discount rate. What's in the News AtriCure reported successful first in human procedures with its dual energy ablation platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation, achieving box lesion creation and pulmonary vein plus posterior wall isolation in under 60 seconds in the first two patients (company announcement).분석 기사 • Dec 11
AtriCure, Inc.'s (NASDAQ:ATRC) 29% Share Price Surge Not Quite Adding Up
AtriCure, Inc. ( NASDAQ:ATRC ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...분석 기사 • Nov 01
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its quarterly results, which were ahead of market...분석 기사 • Aug 01
AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
AtriCure, Inc. ( NASDAQ:ATRC ) investors will be delighted, with the company turning in some strong numbers with its...분석 기사 • Jul 08
AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • May 01
AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch
It's not a stretch to say that AtriCure, Inc.'s ( NASDAQ:ATRC ) price-to-sales (or "P/S") ratio of 3.1x seems quite...분석 기사 • Apr 04
Is AtriCure (NASDAQ:ATRC) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
새로운 내러티브 • Mar 22
cryoSPHERE+ And EnCompass Clamp Launches Will Accelerate Global Adoption
New product launches and international expansion, especially in Europe and China, are key drivers for AtriCure's projected revenue growth and market leadership.분석 기사 • Jan 22
Revenues Tell The Story For AtriCure, Inc. (NASDAQ:ATRC) As Its Stock Soars 29%
AtriCure, Inc. ( NASDAQ:ATRC ) shares have continued their recent momentum with a 29% gain in the last month alone...분석 기사 • Jan 15
Calculating The Fair Value Of AtriCure, Inc. (NASDAQ:ATRC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, AtriCure fair value estimate is US$35.69 With US$34.69 share...분석 기사 • Dec 24
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Nov 06
A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb
Despite an already strong run, AtriCure, Inc. ( NASDAQ:ATRC ) shares have been powering on, with a gain of 28% in the...분석 기사 • Nov 01
US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its third-quarter results, which were ahead of...분석 기사 • Oct 31
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?
AtriCure, Inc. ( NASDAQ:ATRC ), is not the largest company out there, but it saw a significant share price rise of 71...분석 기사 • Oct 02
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price
Key Insights AtriCure's estimated fair value is US$39.81 based on 2 Stage Free Cash Flow to Equity Current share price...분석 기사 • Sep 06
Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce
AtriCure, Inc. ( NASDAQ:ATRC ) shareholders would be excited to see that the share price has had a great month, posting...분석 기사 • Aug 02
Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report
There's been a notable change in appetite for AtriCure, Inc. ( NASDAQ:ATRC ) shares in the week since its...Seeking Alpha • Jul 25
AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care
Summary AtriCure, Inc. is a market leader in surgical solutions for atrial fibrillation, LAA management, and post-operative pain management, serving 2,000 hospitals globally. AtriCure's latest project involves expanding into the European market with innovative products, facing potential regulatory delays and market acceptance challenges. Despite facing competition from major players like Johnson & Johnson and Medtronic, AtriCure's strong revenue growth and innovative product lineup position it for continued success in the market. Read the full article on Seeking Alpha분석 기사 • Jul 18
AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward
AtriCure, Inc. ( NASDAQ:ATRC ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...분석 기사 • May 30
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, AtriCure fair value estimate is US$40.72 AtriCure's US$21.61...분석 기사 • Apr 04
Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump
AtriCure, Inc. ( NASDAQ:ATRC ) shareholders won't be pleased to see that the share price has had a very rough month...분석 기사 • Mar 14
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jan 21
Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues
When close to half the companies in the Medical Equipment industry in the United States have price-to-sales ratios (or...분석 기사 • Nov 29
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...매출 및 비용 세부 내역
매출 및 비용 세부 내역
AtriCure가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 30 Jun 26 | 570 | 11 | 324 | 98 |
| 31 Mar 26 | 552 | -5 | 320 | 101 |
| 31 Dec 25 | 535 | -11 | 311 | 99 |
| 30 Sep 25 | 518 | -29 | 305 | 110 |
| 30 Jun 25 | 500 | -36 | 300 | 108 |
| 31 Mar 25 | 480 | -38 | 295 | 99 |
| 31 Dec 24 | 465 | -45 | 291 | 96 |
| 30 Sep 24 | 448 | -39 | 287 | 82 |
| 30 Jun 24 | 430 | -40 | 275 | 81 |
| 31 Mar 24 | 415 | -37 | 270 | 78 |
| 31 Dec 23 | 399 | -30 | 261 | 74 |
| 30 Sep 23 | 381 | -25 | 245 | 67 |
| 30 Jun 23 | 366 | -28 | 241 | 62 |
| 31 Mar 23 | 349 | -38 | 235 | 59 |
| 31 Dec 22 | 330 | -46 | 231 | 57 |
| 30 Sep 22 | 316 | -56 | 229 | 57 |
| 30 Jun 22 | 303 | 53 | 221 | 54 |
| 31 Mar 22 | 290 | 52 | 214 | 51 |
| 31 Dec 21 | 274 | 50 | 205 | 49 |
| 30 Sep 21 | 259 | 45 | 190 | 46 |
| 30 Jun 21 | 243 | -57 | 174 | 45 |
| 31 Mar 21 | 213 | -49 | 151 | 43 |
| 31 Dec 20 | 207 | -48 | 151 | 43 |
| 30 Sep 20 | 210 | -46 | 147 | 45 |
| 30 Jun 20 | 212 | -50 | 157 | 45 |
| 31 Mar 20 | 230 | -46 | 165 | 45 |
| 31 Dec 19 | 231 | -35 | 167 | 41 |
| 30 Sep 19 | 222 | -23 | 159 | 37 |
| 30 Jun 19 | 216 | -20 | 150 | 35 |
| 31 Mar 19 | 209 | -17 | 144 | 34 |
| 31 Dec 18 | 202 | -21 | 140 | 35 |
| 30 Sep 18 | 195 | -20 | 135 | 34 |
| 30 Jun 18 | 187 | -20 | 130 | 33 |
| 31 Mar 18 | 180 | -27 | 126 | 34 |
| 31 Dec 17 | 175 | -27 | 121 | 34 |
| 30 Sep 17 | 170 | -33 | 116 | 36 |
| 30 Jun 17 | 166 | -32 | 111 | 37 |
| 31 Mar 17 | 160 | -34 | 109 | 37 |
| 31 Dec 16 | 155 | -33 | 105 | 36 |
| 30 Sep 16 | 150 | -36 | 106 | 34 |
| 30 Jun 16 | 143 | -35 | 102 | 32 |
| 31 Mar 16 | 135 | -32 | 97 | 29 |
| 31 Dec 15 | 129 | -27 | 91 | 26 |
| 30 Sep 15 | 123 | -22 | 85 | 23 |
양질의 수익: ATRC는 고품질 수익을 보유하고 있습니다.
이익 마진 증가: ATRC는 과거에 흑자전환했습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: ATRC는 지난 5년 동안 흑자전환하며 연평균 -18.6%의 수익 성장을 기록했습니다.
성장 가속화: ATRC는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.
수익 대 산업: ATRC는 지난해 흑자전환하여 지난 해 수익 성장률을 Medical Equipment 업계(15.6%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: ATRC의 자본 수익률(2%)은 낮음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/09 04:59 |
| 종가 | 2026/09/09 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
AtriCure, Inc.는 19명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |